Vectus Biosystems Limited (VBS) AI Stock Analysis

• Market Cap: AU$2.93M
• Dividend Yield: N/A
• Average Volume (3M): 36.85K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.52
• Revenue Growth: N/A
• EPS Growth: 9.19%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 53,333,332
• 10 Day Avg. Volume: 49,764
• 30 Day Avg. Volume: 36,854
• PEG Ratio: -0.26
• Price to Book (P/B): 4.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: AU$0.00 ▼(-100.00%Downside)

Vectus Biosystems Limited's overall stock score is driven largely by its poor financial performance and valuation. The company's persistent financial challenges and negative earnings impact its attractiveness to investors. While technical analysis indicates some short-term bullish momentum, the overbought conditions suggest potential downside risks. The lack of earnings call and corporate events data means no additional insights were available to affect the score.

Vectus Biosystems Limited Business Overview & Revenue Model

Company Description

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.

How the Company Makes Money

Vectus Biosystems Limited generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company invests in extensive research and development to advance its product pipeline, with a key focus on VB0004. Revenue is expected to be derived from licensing agreements, partnerships with pharmaceutical companies, and potential sales of approved drugs. Strategic collaborations and partnerships play a significant role in funding Vectus' research initiatives and expanding its market reach. The company may also receive milestone payments and royalties from licensing its drug candidates to other entities as they progress through clinical trials and into commercialization.

Vectus Biosystems Limited Financial Statement Overview

Summary

Vectus Biosystems Limited is facing significant financial challenges, characterized by declining revenues, persistent losses, and negative equity. The company needs strategic initiatives to enhance revenue and manage costs effectively.

Income Statement

Vectus Biosystems Limited has demonstrated a declining revenue trend with a negative revenue growth rate from 2023 to 2024. The company is struggling with profitability, reflected in negative net profit and EBIT margins. Despite some gross profit, the overall financial performance remains weak due to high operating losses.

Balance Sheet

The balance sheet shows a significant improvement in debt levels, but the company still faces challenges with negative equity, indicating long-term financial instability. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio remains negative, undermining financial stability.

Cash Flow

The cash flow statement highlights negative operating and free cash flows, with slight improvement in free cash flow from the previous year. The company exhibits a weak operating cash flow to net income ratio, indicating inefficient cash conversion from operations.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	1.14M	1.35M	1.30M	180.00	51.19K
Gross Profit	1.14M	1.31M	1.28M	1.02M	31.67K
EBITDA	-2.27M	-3.19M	-3.28M	-3.71M	-2.64M
Net Income	-2.34M	-3.45M	-3.99M	-3.86M	-3.00M
Balance Sheet
Total Assets	2.03M	4.63M	3.94M	6.98M	3.00M
Cash, Cash Equivalents and Short-Term Investments	808.97K	2.95M	1.28M	5.78M	2.72M
Total Debt	28.93K	70.21K	6.90M	8.68M	8.28M
Total Liabilities	539.26K	1.11M	8.36M	9.88M	9.71M
Stockholders Equity	1.49M	3.52M	-4.42M	-2.90M	-6.71M
Cash Flow
Free Cash Flow	-2.10M	-2.37M	-4.46M	-3.26M	-3.00M
Operating Cash Flow	-2.03M	-2.35M	-4.44M	-3.26M	-3.00M
Investing Cash Flow	-67.90K	-17.13K	-21.00K	0.00	0.00
Financing Cash Flow	-41.28K	4.04M	-34.55K	6.35M	5.64M

Vectus Biosystems Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.06
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 82.50 is Negative, neither overbought nor oversold. The STOCH value of 95.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:VBS.

Vectus Biosystems Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.11	-63.03%	2.07%	16.35%	0.29%
VBS	40 Underperform	AU$2.93M	―	-163.00%	―	―	9.19%
BITRF	―	$2.18M	―	-119.28%	―	―	―
CMB	―	AU$4.84M	―	-983.90%	―	―	―
1AD	46 Neutral	AU$2.23M	―	-392.18%	―	―	34.26%
HXL	40 Underperform	AU$2.17M	―	-45.96%	―	―	-26.67%
ANR	27 Underperform	AU$1.28M	―	-147.32%	―	―	26.09%

Vectus Biosystems Limited Corporate Events

Vectus Biosystems Expands Share Issuance Under Employee Incentive Plan

Vectus Biosystems Limited has issued 55,019 new fully paid ordinary shares to an employee under its Employee Incentive Plan. This move reflects the company’s ongoing efforts to incentivize its workforce and align employee interests with corporate goals, potentially impacting its operational dynamics and stakeholder relations.

Vectus Biosystems Expands Capital with New Securities Issuance

Vectus Biosystems Limited has announced the issuance of 55,019 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure, potentially impacting its financial flexibility and market presence positively.

Vectus Biosystems Issues Unquoted Options to Employees

Vectus Biosystems Limited announced the issuance of 75,000 unquoted options as part of an employee incentive scheme. This move is likely aimed at retaining talent and aligning employee interests with company growth, potentially impacting the company’s operational dynamics and stakeholder relations positively.

Vectus Biosystems Advances VB0004 Commercialization and Seeks Chinese Collaborations

Vectus Biosystems Limited has been actively advancing its commercialization efforts for its lead compound, VB0004, and other drug candidates, with a focus on potential collaborations in China. The company has validated VB0004’s safety profile in recent clinical trials and is exploring faster approval paths in China. Financially, Vectus has reduced operating costs and is seeking licensing opportunities to support further clinical studies, with cash-on-hand reported at $370,000 as of March 2025.